Global epidemiology of rheumatoid arthritis

Finckh, Axel; Gilbert, Benoît; Hodkinson, Bridget; Bae, Sang Cheol; Thomas, Ranjeny; Deane, Kevin D.; Alpizar-Rodriguez, D.; Lauper, Kim

doi:10.1038/s41584-022-00827-y

Cited by 223 publications

(223 citation statements)

References 206 publications

Supporting

Mentioning

215

Contrasting

Unclassified

Order By: Relevance

“…Finally, we identified females aged 60–69 as the group with the highest admission rates, which is consistent with literature [ 28 , 36 , 37 ]. Our data suggests that living in rural areas of WA adds to the possibility of being frequently hospitalised for RA, which could indicate limited local access to primary health care [ 38 ].…”

Section: Discussionsupporting

confidence: 90%

The prevalence of rheumatoid arthritis in Western Australia

et al. 2022

View full text Add to dashboard Cite

Background Rheumatoid arthritis (RA) is the most common form of autoimmune arthritis, but the prevalence in Australia is unknown. We estimated RA period prevalence and identified factors associated with frequent RA hospitalisations, using linked administrative health and state-specific Australian Pharmaceutical Benefits Scheme (PBS) datasets in Western Australia (WA) from 1995 to 2014. Methods This was a longitudinal population-based cohort study using two independent datasets to identify prevalent RA patients. RA prevalence was calculated per 1000 hospital separations and biological therapy users. RA patients were identified in the WA linked health dataset using ICD codes 714.0–714.9 and M05.00–M06.99. Dispensing data on biological therapy for RA were obtained from PBS records and converted to defined daily doses /1000 population/day. Multivariable logistic regression was used to analyse factors associated with frequent RA hospitalisations (> 2/year), controlling for sex, age, and geographic locations. Potential interactions were assessed using logistic regression in a stepwise approach. Results A total of 17,125 RA patients had 50,353 hospital separations between 1995 and 2014, averaging three hospitalisations per patient over 20 years. The RA period prevalence was 3.4 per 1000 separations (0.34%; 95% CI 0.33–0.34), while the RA period prevalence based on biological therapy use was 0.36% (95% CI 0.35–0.37). The corrected RA prevalence based on biological therapy usage was 0.36% (95% CI 0.35–0.37) for the 2005–2009 and increased to 0.72% (95% CI 0.70–0.74) in 2010–2014 period. Associated factors for frequent RA hospitalisations were being female [1.21 (95% CI 1.15–1.26)], aged 60–69 years [4.45 (95% CI 3.74–5.30)], living in rural areas [1.12 (95% CI 1.02–1.24)]. The odd ratio of interaction between these associated factors was 1.34 (95% CI 1.16–1.55). Conclusion The minimal prevalence of RA in Western Australia is 0.34–0.36%, which falls within the literature range. Older female RA patients in rural were more likely to be hospitalised, suggesting unmet primary care for needs.

show abstract

Section: Discussionsupporting

confidence: 90%

The prevalence of rheumatoid arthritis in Western Australia

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The EAE model was established in a previous study by immunizing mice with brain-derived MOG35-55 peptide and, after anti-TIM-4 treatment, it was observed that the clinical symptoms of EAE were markedly improved (8). Rheumatoid arthritis (RA) is a common chronic autoimmune disease (105). Using a model of collagen-induced arthritis (cIA), it was found that injection of an anti-TIM-4 monoclonal antibody into cIA could aggravate the development of RA.…”

Section: Role Of Tim-4 In Viral Infectionmentioning

confidence: 99%

Function and characteristics of TIM‑4 in immune regulation and disease (Review)

Wang

Chen

et al. 2022

Int J Mol Med

View full text Add to dashboard Cite

T-cell/transmembrane immunoglobulin and mucin domain containing 4 (TIM-4) is a phosphatidylserine receptor that is mainly expressed on antigen-presenting cells and is involved in the recognition and efferocytosis of apoptotic cells. TIM-4 has been found to be expressed in immune cells such as natural killer T, B and mast cells and to participate in multiple aspects of immune regulation, suggesting that TIM-4 may be involved in a variety of immune-related diseases. Recent studies have confirmed that TIM-4 is also abnormally expressed in a variety of malignant tumor cells and is closely associated with the occurrence and development of tumors and the tumor immune microenvironment. The present study aimed to describe the expression and functional characteristics of TIM-4 in detail and to comprehensively discuss its role in pathophysiological processes such as infection, allergy, metabolism, autoimmunity and tumor immunity. The current review provided a comprehensive understanding of the functions and characteristics of TIM-4, as well as novel ideas for the diagnosis and treatment of diseases. Contents 1. Introduction 2. Regulatory role of TIM-4 in efferocytosis 3. Functional characteristics of TIM-4 in different immune cells 4. Regulatory role of TIM-4 in the occurrence and development of diseases 5. conclusion

show abstract

“…In Taiwan, the annual incidence rate of RA was 15.8 cases per 100,000 population, and the prevalence rate increased steadily from 57.7 in 2000 to 99.6 per 100,000 people in 2007 [ 12 , 13 ]. RA is characterized by progressive articular damage, potentially leading to functional disability and premature mortality [ 14 ]. RA is also associated with extra-articular manifestations, potentially involving the eyes.…”

Section: Introductionmentioning

confidence: 99%

Rheumatoid Arthritis Associated with Dry Eye Disease and Corneal Surface Damage: A Nationwide Matched Cohort Study

Lai

Wang

et al. 2023

IJERPH

View full text Add to dashboard Cite

Rheumatoid arthritis is potentially connected to ocular disorders, such as corneal inflammation and lacrimal gland destruction. This study aimed to evaluate the risk of dry eye disease (DED) and corneal surface damage among patients with rheumatoid arthritis. In a nationwide cohort study, we utilized Taiwan’s National Health Insurance research database and conducted propensity score matching to compare the risks of DED and corneal surface damage between patients with and without rheumatoid arthritis. Proportional hazards regression analyses were used to calculate the adjusted hazard ratio (aHR) and 95% confidence interval (CI) for the outcomes of interest. The matching procedure generated 33,398 matched pairs with 501,377 person-years of follow-up for analyses. The incidence of DED was 23.14 and 10.25 per 1000 person-years in patients with and without rheumatoid arthritis, respectively. After adjusting for covariates, rheumatoid arthritis was significantly associated with DED (aHR: 2.03, 95% CI: 1.93–2.13, p < 0.0001). The association was generally consistent across the subgroups of age, sex, use of systemic corticosteroids, and different comorbidity levels. In addition, patients with rheumatoid arthritis had a higher risk of corneal surface damage (aHR: 1.36, 95% CI: 1.21–1.51, p < 0.0001) compared to control subjects. Other independent factors for corneal surface damage were age and sleeping disorders. Rheumatoid arthritis was associated with an increased risk of DED and corneal surface damage. Ophthalmological surveillance is required to prevent vision-threatening complications in this susceptible population.

show abstract

Global epidemiology of rheumatoid arthritis

Cited by 223 publications

References 206 publications

The prevalence of rheumatoid arthritis in Western Australia

The prevalence of rheumatoid arthritis in Western Australia

Function and characteristics of TIM‑4 in immune regulation and disease (Review)

Rheumatoid Arthritis Associated with Dry Eye Disease and Corneal Surface Damage: A Nationwide Matched Cohort Study

Contact Info

Product

Resources

About